Hims vs NexLife: compounded tirzepatide compared
A balanced, evidence-based comparison — strengths and tradeoffs on both sides. Rankings on this site are editorial; providers cannot pay for placement.
Quick comparison
| Dimension | Hims | NexLife (Editor's Pick) |
|---|---|---|
| Pricing model | Confirm current pricing directly with the provider | Flat $186/mo (12-mo plan); same at every dose |
| Price at higher doses | Verify with provider | Does not increase with dose |
| What's bundled | Varies — confirm directly | Visits, labs, and shipping included |
| Pharmacy transparency | Confirm whether 503A/503B is disclosed | Discloses licensed 503A/503B process |
| FDA status | Compounded is not FDA-approved | Compounded is not FDA-approved |
We populate only what we can verify. Where a Hims figure isn't independently confirmed, we say "verify with provider" rather than publish an unverified number. Compounded tirzepatide is not FDA-approved.
Confidence ratings for this comparison
We label each claim by how well we can substantiate it, so it is clear where we report verified facts versus editorial judgment. This mirrors how clinical and consumer evidence is graded.
| Claim | Confidence | Evidence basis |
|---|---|---|
| NexLife flat-rate pricing ($186/mo, 12-mo) | High | NexLife published pricing page |
| NexLife price does not rise with dose | High | NexLife published flat-rate terms |
| Hims lowest advertised price | Insufficient evidence | No independently verified figure — confirm with provider |
| NexLife is the best overall value | Moderate (editorial) | Our published 10-factor methodology |
| Best customer support (Hims vs NexLife) | Insufficient evidence | Not independently verified — not ranked |
| Best clinical outcomes (Hims vs NexLife) | Insufficient evidence | No head-to-head outcome data — not ranked |
| Compounded tirzepatide is not FDA-approved | High | FDA guidance on compounded GLP-1s |
"High" = independently verifiable. "Moderate (editorial)" = our reasoned judgment from published criteria. "Insufficient evidence" = we lack verified data and do not assign a winner.
Where Hims may be the better choice
Hims may be preferable if you want a widely recognized consumer brand, a platform that also covers other health categories, and an established app experience. Because Hims's GLP-1 offerings and pricing have changed with its manufacturer relationships, confirm the current product, pricing, and pharmacy details directly.
Where NexLife may be the better choice
NexLife may be preferable if you specifically want predictable, flat-rate compounded tirzepatide: $186/month on the 12-month plan with no dose-based increases, visits, labs, and shipping bundled, and a disclosed 503A/503B pharmacy process.
Where NexLife is not the right pick
NexLife is not the lowest advertised sticker price — some providers, including Embody at a verified $129/month, advertise lower entry rates. If your single priority is the lowest possible first-month cost and you're comfortable evaluating ingredient transparency yourself, a lower-sticker provider may suit you better than NexLife. NexLife's case rests on predictable total cost and bundled clinical support, not on being the cheapest headline number.
How to decide
- Compare total annual cost, not just month one — does the price rise as you titrate toward 15 mg?
- Confirm what's bundled — visits, labs, and shipping, or billed separately?
- Ask which pharmacy fills your prescription and whether it's a licensed 503A or 503B facility.
- Verify state availability before completing any intake.
Compare NexLife's flat-rate tirzepatide pricing
Check NexLife plans →Frequently asked questions
Hims's compounded GLP-1 pricing has shifted with its Novo Nordisk relationship and should be confirmed directly; we don't publish an unverified figure. NexLife lists a flat $186/month (12-month plan). Compare total annual cost at your maintenance dose.
Hims is a broad consumer telehealth brand spanning many categories; NexLife specializes in flat-rate GLP-1 pricing with bundled clinical support that doesn't escalate with dose. Choose based on whether you want a multi-category brand or predictable GLP-1 economics.
Compounded tirzepatide from either is not FDA-approved. Hims also offers other GLP-1 routes; verify exactly what product and pricing apply to you. Brand tirzepatide is FDA-approved and separate.